GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zevra Therapeutics Inc (FRA:1GDA) » Definitions » 3-Year FCF Growth Rate

Zevra Therapeutics (FRA:1GDA) 3-Year FCF Growth Rate : -24.40% (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Zevra Therapeutics 3-Year FCF Growth Rate?

Zevra Therapeutics's Free Cash Flow per Share for the three months ended in Mar. 2024 was €-0.36.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -24.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 11 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Zevra Therapeutics was 76.10% per year. The lowest was -55.00% per year. And the median was -3.00% per year.


Competitive Comparison of Zevra Therapeutics's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Zevra Therapeutics's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zevra Therapeutics's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zevra Therapeutics's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Zevra Therapeutics's 3-Year FCF Growth Rate falls into.



Zevra Therapeutics 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Zevra Therapeutics  (FRA:1GDA) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Zevra Therapeutics 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Zevra Therapeutics's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Zevra Therapeutics (FRA:1GDA) Business Description

Traded in Other Exchanges
Address
1180 Celebration Boulevard, Suite 103, Celebration, FL, USA, 34747
Zevra Therapeutics Inc is a rare disease company melding science, data and patient needs to create transformational therapies for diseases with limited or no treatment options. The firm's data-driven clinical, regulatory, and commercialization strategies overcome complex drug development challenges to bring much-needed therapies to patients. Its product candidate comprises Arimoclomol, orally delivered investigational product candidate for the treatment of Niemann-Pick type C (NPC). KP1077 is Zevra's lead clinical candidate being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy.

Zevra Therapeutics (FRA:1GDA) Headlines

No Headlines